Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $41.00.

A number of analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $27.79 on Wednesday. The business’s 50 day moving average is $27.20 and its two-hundred day moving average is $22.31. Enliven Therapeutics has a 1-year low of $13.30 and a 1-year high of $30.98. The stock has a market capitalization of $1.66 billion, a P/E ratio of -14.94 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, equities research analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Activity

In other Enliven Therapeutics news, Director Richard A. Heyman sold 9,635 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $25.03, for a total value of $241,164.05. Following the completion of the sale, the director owned 25,545 shares of the company’s stock, valued at $639,391.35. This trade represents a 27.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph P. Lyssikatos sold 91,198 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.22, for a total value of $2,482,409.56. Following the transaction, the insider owned 765,188 shares of the company’s stock, valued at $20,828,417.36. This trade represents a 10.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 237,180 shares of company stock valued at $6,301,233 in the last quarter. 25.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vestal Point Capital LP boosted its holdings in Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares during the period. TCG Crossover Management LLC purchased a new stake in Enliven Therapeutics in the second quarter worth $9,990,000. Duquesne Family Office LLC lifted its position in shares of Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after purchasing an additional 484,405 shares during the last quarter. Spruce Street Capital LP bought a new stake in shares of Enliven Therapeutics during the fourth quarter worth $6,870,000. Finally, Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 13.5% during the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after purchasing an additional 418,673 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.